Institution
University of Lorraine
Education•Nancy, France•
About: University of Lorraine is a education organization based out in Nancy, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 11942 authors who have published 25010 publications receiving 425227 citations. The organization is also known as: Lorraine University.
Papers published on a yearly basis
Papers
More filters
••
University of Cincinnati1, American Society of Clinical Oncology2, University of California, San Francisco3, University of Lorraine4, Hastings Entertainment5, Memorial Sloan Kettering Cancer Center6, University of Utah7, Veterans Health Administration8, Stanford University9, Cleveland Clinic10, Pancreatic Cancer Action Network11, University of Texas MD Anderson Cancer Center12, Cornell University13, University of Michigan14, Duke University15, Johns Hopkins University16
TL;DR: An update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment and new or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided.
Abstract: PURPOSEThe aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment.METHODSASCO c...
128 citations
••
TL;DR: Different experiences of integrating patients as full patient research partners in outcomes research from multiple perspectives are described, drawing from three real-world examples, to suggest basic guidelines for outcomes researchers on establishing research partnerships with patients.
127 citations
••
TL;DR: Early β blocker use was associated with reduced 30 day mortality in patients with acute myocardial infarction, and discontinuation of β blockers at one year was not associated with higher five year mortality, leaving the utility of prolonged β blocker treatment in patients without heart failure or left ventricular dysfunction questioned.
Abstract: OBJECTIVE
To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction.
DESIGN
Multicentre prospective cohort study.
SETTING
Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005.
PARTICIPANTS
2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction.
MAIN OUTCOME MEASURES
Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use.
RESULTS
beta blockers were used early in 77% (2050/2679) of patients, were prescribed at discharge in 80% (1783/2217), and were still being used in 89% (1230/1383) of those alive at one year. Thirty day mortality was lower in patients taking early beta blockers (adjusted hazard ratio 0.46, 95% confidence interval 0.26 to 0.82), whereas the hazard ratio for one year mortality associated with beta blockers at discharge was 0.77 (0.46 to 1.30). Persistence of beta blockers at one year was not associated with lower five year mortality (hazard ratio 1.19, 0.65 to 2.18). In contrast, five year mortality was lower in patients continuing statins at one year (hazard ratio 0.42, 0.25 to 0.72) compared with those discontinuing statins. Propensity score and sensitivity analyses showed consistent results.
CONCLUSIONS
Early beta blocker use was associated with reduced 30 day mortality in patients with acute myocardial infarction, and discontinuation of beta blockers at one year was not associated with higher five year mortality. These findings question the utility of prolonged beta blocker treatment after acute myocardial infarction in patients without heart failure or left ventricular dysfunction.
127 citations
••
TL;DR: The roles played by cellular stress and its responses in shaping metabolic disorders are discussed and current mechanistic insights explaining the pathogenesis of these disorders are summarized.
Abstract: Metabolic disorders have become among the most serious threats to human health, leading to severe chronic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease, as well as cardiovascular diseases. Interestingly, despite the fact that each of these diseases has different physiological and clinical symptoms, they appear to share certain pathological traits such as intracellular stress and inflammation induced by metabolic disturbance stemmed from over nutrition frequently aggravated by a modern, sedentary life style. These modern ways of living inundate cells and organs with saturating levels of sugar and fat, leading to glycotoxicity and lipotoxicity that induce intracellular stress signaling ranging from oxidative to ER stress response to cope with the metabolic insults (Mukherjee, et al., 2015). In this review, we discuss the roles played by cellular stress and its responses in shaping metabolic disorders. We have summarized here current mechanistic insights explaining the pathogenesis of these disorders. These are followed by a discussion of the latest therapies targeting the stress response pathways.
127 citations
••
TL;DR: Comparison of PNEC with measured environmental concentrations indicate that, for the present, environmental risks deriving from lanthanides should be limited to some hotspots (e.g., downstream of wastewater treatment plants), however, considering the increasing environmental concentrations of lanthanide, the associated risks could become higher in the future.
127 citations
Authors
Showing all 12161 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jonathan I. Epstein | 138 | 1121 | 80975 |
Peter Tugwell | 129 | 948 | 125480 |
David Brown | 105 | 1257 | 46827 |
Faiez Zannad | 103 | 839 | 90737 |
Sabu Thomas | 102 | 1554 | 51366 |
Francis Martin | 98 | 733 | 43991 |
João F. Mano | 97 | 822 | 36401 |
Jonathan A. Epstein | 94 | 299 | 27492 |
Muhammad Imran | 94 | 3053 | 51728 |
Laurent Peyrin-Biroulet | 90 | 901 | 34120 |
Athanase Benetos | 83 | 391 | 31718 |
Michel Marre | 82 | 444 | 39052 |
Bruno Rossion | 80 | 337 | 21902 |
Lyn March | 78 | 367 | 62536 |
Alan J. M. Baker | 76 | 234 | 26080 |